Six months after patients switched from reference infliximab to biosimilar infliximab, there was no meaningful increase in patients’ outpatient healthcare use, according to a new study.
While switching medically stable patients from reference biologics to cheaper biosimilars has the potential to generate significant cost savings for health systems, some recent studies have suggested that these nonmedical switches could actually lead to higher costs because of increased healthcare utilization.
A study published this month in RMD Open sought to examine whether a large, mandatory nonmedical switch to a biosimilar in Danish patients with inflammatory arthritis changed their resource utilization, and found that, 6 months after switching, there was no meaningful increase in patients’ outpatient healthcare use.
In May 2015, Danish national guidelines mandated a switch from reference infliximab, Remicade, to biosimilar CT-P13 (sold as Inflectra in the United States and as Remsima in other territories) in order to benefit from the 36% lower cost of the biosimilar. The DANBIO registry, which collects clinical information among all Danish patients with inflammatory diseases, offered a chance for investigators to assess healthcare utilization 6 months pre- and 6 months postswitch.
The study population included 769 patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who switched from the reference to the biosimilar infliximab in 2016. The patients had a total of 2995 visits to healthcare providers in the 6 months before switching, 689 visits on the date of switching, and 3034 visits up to 6 months after the switch. In total, 19,752 services (such as consultation, guidance, administration of infliximab or methotrexate, observation, and similar services) were provided to patients, 2019 of which were provided on the switch date. The weekly rate of visits per patient was stable during the full time period investigated.
The total number of days with services provided in the preswitch period was 4131, and in the postswitch period, 4400. Rates of services provided declined after switching, but there was an increase in telephone consultation, patient guidance, intravenous medication, clinical investigation and controls, and patient observation. However, the numerical differences in services provided were close to zero.
The authors concluded that their study showed no evidence of increased outpatient healthcare utilization following the nationwide switch.
“It is reassuring that we found only minor changes in the use of healthcare resources, despite the switch being mandatory and that no specific strategy for patient information was set up,” and they indicated that “the fact that patients were informed about the switch at an already scheduled appointment could potentially reduce the nocebo effect.”
Reference
Glintborg B, Sørensen, Hetland ML. Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis. RMD Open. 2018;4(2): e000710. doi: 10.1136/rmdopen-2018-000710.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.